ClinicalTrials.gg

Program

Lidocaine

Also written as “Lidoderm®”, “Lidocaine topical system 1.8%” and “Lidoderm”.

Its studies are mostly in Pain · Neuralgia, Postherpetic · Attention Deficit Disorder with Hyperactivity · Osteoarthritis, Knee · Low Back Pain, led by 25 companies.

Furthest: phase 4, since May 15, 200954 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keenova Therapeutics110 open or runningphase 4since May 15, 2009Dec 15, 2005none ahead
Scilex Pharmaceuticals80 open or runningphase 1since Oct 28, 2019Oct 28, 2019none ahead
ZARS Pharma60 open or runningphase 4since Sep 3, 2008Sep 3, 2008none ahead
Grünenthal40 open or runningphase 3since Sep 12, 2012Jul 1, 2010none ahead
AlgoRx Pharmaceuticals30 open or runningphase 3since Aug 31, 2005Aug 15, 2005none ahead
PhenoSolve30 open or runningearly phase 1since Sep 17, 2018Sep 17, 2018none ahead
Astellas Pharma10 open or runningphase 4since Aug 11, 2011Aug 11, 2011none ahead
AstraZeneca10 open or runningearly phase 1since Feb 16, 2011Feb 16, 2011none ahead
cartiva-inc10 open or runningphase 2since Feb 17, 2014Feb 17, 2014none ahead
centrexion-therapeutics10 open or runningphase 1since Feb 9, 2015Feb 9, 2015none ahead
chemische-fabrik-kreussler-co-gmbh10 open or runningphase 4since Nov 14, 2017Nov 14, 2017none ahead
Galderma Group10 open or runningphase 4since Feb 24, 2012Feb 24, 2012none ahead
Hamad Medical10 open or runningphase 3since Sep 10, 2020Sep 10, 2020none ahead
Ipsen10 open or runningphase 2since Sep 6, 2018Sep 6, 2018none ahead
isdin10 open or runningphase 2since May 24, 2011May 24, 2011none ahead
isifer-ab10 open or runningphase 2since Apr 4, 2011Apr 4, 2011none ahead
j-a-r-laboratories10 open or runningno phasesince Apr 18, 2016Apr 18, 2016none ahead
juniper-pharmaceuticals-inc10 open or runningphase 2since Mar 28, 2008Mar 28, 2008none ahead
Lee's Pharmaceutical10 open or runningphase 3since Aug 28, 2018Aug 28, 2018none ahead
lumara-health-inc10 open or runningphase 2since Dec 26, 2007Dec 26, 2007none ahead
Mundipharma10 open or runningphase 3since May 20, 2015May 20, 2015none ahead
Novartis10 open or runningphase 3since Dec 20, 2010Dec 20, 2010none ahead
Orexa BV11 open or runningphase 2since Jun 9, 2023Jun 9, 2023none ahead
Sarah Cannon Research Institute10 open or runningphase 2since Dec 4, 2012Dec 4, 2012none ahead
scivision-biotech-inc10 open or runningno phasesince Dec 4, 2013Dec 4, 2013none ahead

Also a collaborator on its studies: prevail-infoworks, qps-holdings-llc, anfomed-gmbh and nuvo-research-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 34 studies since Aug 15, 2005.

  1. May 20, 2015Mundipharma's first study: phase 3 study in Herpes Zoster PainNew to MundipharmaMundipharma · NCT02452112 · 243 enrolled · China
  2. Apr 18, 2016j-a-r-laboratories's first study: no phase study in Back PainNew to j-a-r-laboratoriesj-a-r-laboratories · NCT02749123 · 100 enrolled · United States
  3. Nov 14, 2017chemische-fabrik-kreussler-co-gmbh's first study: phase 4 study in PeriodontitisNew to chemische-fabrik-kreussler-co-gmbhchemische-fabrik-kreussler-co-gmbh · NCT03354312 · 94 enrolled · Germany
  4. Aug 28, 2018Lee's Pharmaceutical's first study: phase 3 study in Acute PainNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT03653260 · 288 enrolled · China
  5. Sep 6, 2018Ipsen's first study: phase 2 study in Chronic Scar PainNew to IpsenIpsen · NCT03663101 · 16 enrolled · United Kingdom
  6. Sep 17, 2018PhenoSolve's first studies: 2 early phase 1 studies in Attention Deficit Disorder with HyperactivityNew to PhenoSolvePhenoSolve · NCT03680885, NCT03676725
  7. Nov 15, 20182 phase 3 studies in Neuralgia, PostherpeticGrünenthal · NCT03745404, NCT03765697
  8. Oct 28, 2019Scilex Pharmaceuticals's first studies: 3 phase 1 studies in HealthyNew to Scilex PharmaceuticalsScilex Pharmaceuticals · NCT04144192, NCT04150536, NCT04149938
  9. Nov 12, 2019Early phase 1 study in Attention Deficit Disorder with HyperactivityPhenoSolve · NCT04167189 · 28 enrolled · United States
  10. Mar 16, 20203 phase 1 studies in HealthyScilex Pharmaceuticals · NCT04312750, NCT04320173, NCT04319926
  11. Sep 10, 2020Hamad Medical's first study: phase 3 study in Pain, ProceduralNew to Hamad MedicalHamad Medical · NCT04571879 · 48 enrolled · Qatar
  12. Mar 3, 2021Phase 1 study in HealthyScilex Pharmaceuticals · NCT04784728 · 24 enrolled · United States
  13. Oct 11, 2021Phase 1 study in HealthyScilex Pharmaceuticals · NCT05106400 · 24 enrolled · United States
  14. Jun 9, 2023Orexa BV's first study: phase 2 study in Ileus PostoperativeNew to Orexa BVOrexa BV · NCT05923086 · 126 planned · Germany

TargetBeta

“Sodium channel alpha subunit blocker; Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 54 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05923086Ileus Postoperative · Germany2RecruitingOrexa BVDec 31, 2025126
NCT05106400Healthy · United States1CompletedScilex PharmaceuticalsJul 21, 202124
NCT04784728Healthy · United States1CompletedScilex PharmaceuticalsAug 31, 201924
NCT04571879Pain, Procedural · Qatar3UNKNOWNHamad MedicalDec 30, 202348
NCT04320173Healthy · United States1CompletedScilex PharmaceuticalsMar 22, 201747
NCT04319926Healthy · United States1CompletedScilex PharmaceuticalsSep 9, 201824
NCT04312750Healthy1CompletedScilex PharmaceuticalsDec 201554
NCT04167189Attention Deficit Disorder with Hyperactivity · United StatesEarly 1CompletedPhenoSolveMar 30, 202028
NCT04150536Healthy1CompletedScilex PharmaceuticalsJan 25, 201612
NCT04149938Healthy1CompletedScilex PharmaceuticalsOct 27, 201654
NCT04144192Healthy1CompletedScilex PharmaceuticalsJul 24, 201458
NCT03765697Neuralgia, Postherpetic3CompletedGrünenthalJul 12, 2005259
NCT03745404Neuralgia, Postherpetic3CompletedGrünenthalJun 30, 2004265
NCT03680885Attention Deficit Disorder with Hyperactivity · United StatesEarly 1CompletedPhenoSolveMar 30, 202020
NCT03676725Attention Deficit Disorder with Hyperactivity · United StatesEarly 1CompletedPhenoSolveMar 1, 202090
NCT03663101Chronic Scar Pain · United Kingdom2CompletedIpsenNov 8, 201916
NCT03653260Acute Pain · China3CompletedLee's PharmaceuticalFeb 28, 2019288
NCT03354312Periodontitis · Germany4Completedchemische-fabrik-kreussler-co-gmbhNov 2, 201894
NCT02749123Back Pain · United States–UNKNOWNj-a-r-laboratoriesMay 2016100
NCT02452112Herpes Zoster Pain · China3CompletedMundipharmaDec 30, 2015243
NCT02679339Acute-onset Herpes Zoster Pain · Australia1Terminatedcentrexion-therapeuticsAug 20151
NCT02066844Hip Fractures · United States2Completedcartiva-incAug 201440
NCT02006173Pain · Taiwan–Withdrawnscivision-biotech-incJul 20150
NCT01744197Pain · United States2CompletedSarah Cannon Research InstituteFeb 201361
NCT01752322Pain · Austria, Belgium, Brazil and more3CompletedGrünenthalJun 2016444
NCT01602757Healthy · United States1CompletedZARS PharmaMar 201012
NCT01545765Healthy Volunteers · United States4CompletedGalderma GroupMay 201230
NCT01416116Peripheral Nerve Injuries · Belgium, Czechia, Denmark and more4CompletedAstellas PharmaApr 25, 2012122
NCT01360749Agnosia · Spain2CompletedisdinNov 201142
NCT01329796Endometriosis · Sweden2Completedisifer-abJun 200942
NCT01298310Morton Neuroma · SwedenEarly 1CompletedAstraZenecaMay 201227
NCT01265446Pharyngitis · Germany3CompletedNovartisApr 2011250
NCT01155986Pain · France2TerminatedGrünenthalNov 201274
NCT01111773Patellar Tendinopathy · United States2CompletedZARS PharmaMar 201113
NCT01106989Myofascial Pain Syndromes · United States2CompletedZARS PharmaDec 201020
NCT01055444Shoulder Impingement Syndrome · United States2CompletedZARS PharmaAug 201020
NCT00991068Carpal Tunnel Syndrome · United States2CompletedZARS PharmaMar 201024
NCT00904605Osteoarthritis, Knee · United States4TerminatedKeenova TherapeuticsNov 2004
NCT00904540Acute and Chronic Non-radicular LBP · United States4CompletedKeenova TherapeuticsOct 2002131
NCT00904475Chronic Low Back Pain · United States4CompletedKeenova TherapeuticsApr 2003102
NCT00904462Osteoarthritis, Knee · United States2CompletedKeenova TherapeuticsSep 2005224
NCT00904397Chronic Low Back Pain · United States4TerminatedKeenova TherapeuticsNov 200498
NCT00904202Neuralgia, Postherpetic · United States4CompletedKeenova TherapeuticsJun 200362
NCT00904111Chronic Low Back Pain · United States2CompletedKeenova TherapeuticsOct 2005215
NCT00904020Neuralgia, Postherpetic · United States4CompletedKeenova TherapeuticsNov 2002107
NCT00903851Diabetes Mellitus · United States4CompletedKeenova TherapeuticsJun 200376
NCT00747669Pain · United States4SuspendedZARS PharmaApr 201311
NCT00651313Dysmenorrhea · United States2Completedjuniper-pharmaceuticals-incJun 200881
NCT00590590Vulvodynia · United States, Canada2Completedlumara-health-incJun 2009105
NCT00589979Osteoarthritis, Knee · United States2CompletedKeenova TherapeuticsJun 2008169
NCT00266214Carpal Tunnel Syndrome · United States3TerminatedKeenova TherapeuticsJan 2007210
NCT00146185Pain · United States3CompletedAlgoRx Pharmaceuticals504
NCT00140088Pain, Procedural · United States3CompletedAlgoRx Pharmaceuticals504
NCT00132405Pain · United States2CompletedAlgoRx Pharmaceuticals260

How it is read

Names in the registry

  • “Lidocaine”, 8 entries
  • “Lidoderm®”, 5 entries
  • “Lidocaine topical system 1.8%”, 4 entries
  • “Lidoderm”, 4 entries
  • “Lidocaine 5% medicated plaster”, 3 entries

Codes read as this program: CNTX2022.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.